Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal transplant to eradicate colonization with extensively drug-resistant bacteria
2014-003048-11Phase 4Active
- Sponsor
- GIPIT
- Start
- Jun 2015
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of allogeneic fecal microbiota in Gastrointestinal colonization with extensively drug-resistant bacteria (XDR-GIC), Glycopeptide-resistant enterococci colonization and Carbapenem-resistant Enterobacteriaceae colonization, sponsored by GIPIT. Primary endpoint: Negativation of rectal swab. Started Jun 2015; status: active.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Gastrointestinal colonization with extensively drug-resistant bacteria (XDR-GIC)Glycopeptide-resistant enterococci colonizationCarbapenem-resistant Enterobacteriaceae colonization
Beyond the preview
Go deeper on 2014-003048-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003048-11.